Semaglutide is a metabolic regulatory product from the GLP-1 class, focused on supporting appetite control, energy metabolism, and eating behavior management. Due to its effect on appetite signaling and metabolic adaptation mechanisms, the product is considered a modern element of weight management, metabolic balance, and systemic support programs for body weight reduction.
Within weight correction programs, Semaglutide is used gradually, with step-by-step dose titration, allowing the body to adapt to changes in metabolic load and promoting a smoother physiological response to the course. A gradual approach to use helps take into account individual characteristics of metabolic processes and may reduce the likelihood of pronounced digestive system reactions.
Indicative scheme for Semaglutide:
| Period | Dose |
|---|---|
| Weeks 1–4 | 0.25 mg once weekly |
| Weeks 5–8 | 0.5 mg once weekly |
| Weeks 9–12 | 1 mg once weekly |
| Weeks 13–16 | 1.7 mg once weekly |
| From week 17 | 2.4 mg once weekly |
If referring to semaglutide-based products for glucose control support, therapy usually begins with minimal dosages, followed by a gradual increase depending on individual tolerability and program goals.
It is not recommended to start use immediately with high dosages, as this may increase the likelihood of pronounced gastrointestinal discomfort and disrupt the body’s adaptation to the course. It is also not recommended to independently combine several GLP-1 products without specialist supervision.
The usage regimen is selected individually, taking into account the program goals, characteristics of metabolic response, and the overall functional state of the body. Before use, it is recommended to review the product information and consult a specialist.
There are no reviews for this product, be the first to leave your review.
No questions about this product, be the first and ask your question.